International Assets Investment Management LLC Decreases Position in Novo Nordisk A/S (NYSE:NVO)

International Assets Investment Management LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 98.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,908 shares of the company’s stock after selling 1,793,663 shares during the period. International Assets Investment Management LLC’s holdings in Novo Nordisk A/S were worth $1,742,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DSM Capital Partners LLC grew its position in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after buying an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S in the third quarter valued at $98,765,000. Marshall Wace LLP grew its holdings in shares of Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth about $42,017,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $41,646,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Up 2.7 %

NVO stock opened at $85.63 on Thursday. The stock has a market capitalization of $384.27 billion, a PE ratio of 27.71, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a fifty day moving average of $101.38 and a 200-day moving average of $120.03. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.